Given the recent development of multiple PTK6 small molecule inhibitors, our ongoing studies will assess the efficacy of PTK6 inhibitor treatment, alone or in combination with endocrine therapy, with respect to suppression of ER+ breast cancer cell growth. This evidence concerns the gene ESR1 and breast cancer.